JP2020515256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515256A5 JP2020515256A5 JP2019553013A JP2019553013A JP2020515256A5 JP 2020515256 A5 JP2020515256 A5 JP 2020515256A5 JP 2019553013 A JP2019553013 A JP 2019553013A JP 2019553013 A JP2019553013 A JP 2019553013A JP 2020515256 A5 JP2020515256 A5 JP 2020515256A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen
- mutant
- binding
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 82
- 102000036639 antigens Human genes 0.000 claims description 82
- 108091007433 antigens Proteins 0.000 claims description 82
- 102000005962 receptors Human genes 0.000 claims description 62
- 108020003175 receptors Proteins 0.000 claims description 62
- 230000003834 intracellular effect Effects 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 15
- 230000011664 signaling Effects 0.000 claims description 15
- 230000035772 mutation Effects 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000004873 anchoring Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 8
- 108010087819 Fc receptors Proteins 0.000 claims description 7
- 102000009109 Fc receptors Human genes 0.000 claims description 7
- 230000003211 malignant effect Effects 0.000 claims description 7
- 108010073807 IgG Receptors Proteins 0.000 claims description 6
- 102000009490 IgG Receptors Human genes 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 4
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 102000007000 Tenascin Human genes 0.000 claims 2
- 108010008125 Tenascin Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 description 4
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023050868A JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163090 | 2017-03-27 | ||
| EP17163090.8 | 2017-03-27 | ||
| PCT/EP2018/057566 WO2018177966A1 (en) | 2017-03-27 | 2018-03-26 | Improved antigen binding receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023050868A Division JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515256A JP2020515256A (ja) | 2020-05-28 |
| JP2020515256A5 true JP2020515256A5 (https=) | 2021-04-30 |
Family
ID=58428198
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553013A Pending JP2020515256A (ja) | 2017-03-27 | 2018-03-26 | 改良された抗原結合受容体 |
| JP2023050868A Active JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023050868A Active JP7642010B2 (ja) | 2017-03-27 | 2023-03-28 | 改良された抗原結合受容体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11679127B2 (https=) |
| EP (1) | EP3600407B1 (https=) |
| JP (2) | JP2020515256A (https=) |
| KR (1) | KR102712254B1 (https=) |
| CN (1) | CN110662560B (https=) |
| AU (1) | AU2018241624B2 (https=) |
| BR (1) | BR112019020168A2 (https=) |
| CA (1) | CA3056837A1 (https=) |
| CL (1) | CL2019002717A1 (https=) |
| CR (1) | CR20190440A (https=) |
| ES (1) | ES3010117T3 (https=) |
| IL (1) | IL269531B2 (https=) |
| MA (2) | MA49990A (https=) |
| MX (1) | MX2019011526A (https=) |
| MY (1) | MY205503A (https=) |
| PE (1) | PE20200152A1 (https=) |
| SG (1) | SG11201908796XA (https=) |
| TW (1) | TWI890655B (https=) |
| UA (1) | UA128717C2 (https=) |
| WO (1) | WO2018177966A1 (https=) |
| ZA (1) | ZA201906358B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| US10696722B2 (en) | 2016-08-10 | 2020-06-30 | Ajou University Industry-Academic Cooperation Foundation | Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| SG11202104136YA (en) | 2018-10-23 | 2021-05-28 | Dragonfly Therapeutics Inc | Heterodimeric fc-fused proteins |
| WO2020127628A1 (en) * | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Tumor-targeted superagonistic cd28 antigen binding molecules |
| UA128001C2 (uk) * | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| WO2020190936A1 (en) * | 2019-03-18 | 2020-09-24 | Svenska Vaccinfabriken Produktion Ab | Chimeric antigen receptors directed to cells expressing the sodium taurocholate co-transporting receptor |
| CN114007643A (zh) * | 2019-04-19 | 2022-02-01 | 中外制药株式会社 | 识别抗体改变部位的嵌合受体 |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
| CN115916830A (zh) * | 2020-06-25 | 2023-04-04 | 豪夫迈·罗氏有限公司 | 抗cd3/抗cd28双特异性抗原结合分子 |
| CN116194124A (zh) | 2020-07-31 | 2023-05-30 | 中外制药株式会社 | 包含表达嵌合受体的细胞的药物组合物 |
| WO2022029051A1 (en) * | 2020-08-03 | 2022-02-10 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| CA3188867A1 (en) | 2020-08-20 | 2022-02-24 | Xueyin Wang | Compositions and methods for treating ceacam positive cancers |
| CN111995689B (zh) * | 2020-08-27 | 2023-05-05 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| JP2023547447A (ja) * | 2020-10-28 | 2023-11-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 改良型抗原結合受容体 |
| EP4373859A1 (en) | 2021-07-22 | 2024-05-29 | F. Hoffmann-La Roche AG | Heterodimeric fc domain antibodies |
| IL312652A (en) * | 2021-11-25 | 2024-07-01 | Hoffmann La Roche | Enhanced receptors for antigen binding |
| CN116162168A (zh) * | 2021-11-25 | 2023-05-26 | 信达细胞制药(苏州)有限公司 | 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用 |
| CN116284385A (zh) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用 |
| CN119095881A (zh) * | 2022-03-25 | 2024-12-06 | 豪夫迈·罗氏有限公司 | 经改善的嵌合受体 |
| US20250262242A1 (en) | 2022-06-15 | 2025-08-21 | Immunoscape Pte. Ltd. | Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof |
| AR130387A1 (es) | 2022-09-08 | 2024-12-04 | Hoffmann La Roche | Receptores de linfocitos t recombinantes |
| CN120265319A (zh) * | 2022-09-20 | 2025-07-04 | 丹娜-法伯癌症研究院 | 受体介导的胞吞作用用于膜蛋白和货物的靶向内化和降解 |
| CR20250288A (es) | 2023-01-20 | 2025-08-29 | Hoffmann La Roche | POLIPÉPTIDOS DE DOMINIO Fc -VARIANTE DE IL2 RECOMBINANTES Y POLITERAPIA CON POLIPÉPTIDOS DE UNIÓN AL ANTÍGENO ANCLADOS A LA MEMBRANA |
| CN121240874A (zh) | 2023-06-06 | 2025-12-30 | 豪夫迈·罗氏有限公司 | 开关受体 |
| WO2024251132A1 (zh) * | 2023-06-06 | 2024-12-12 | 信达细胞制药(苏州)有限公司 | 一种包含bcma pg car-t细胞制剂和pg抗体制剂的药物组合制剂及其用途 |
| WO2025146286A1 (en) | 2024-01-04 | 2025-07-10 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
| WO2025181329A1 (en) | 2024-03-01 | 2025-09-04 | Immunoscape Pte. Ltd. | Human t cell receptors and uses thereof |
| WO2025233304A1 (en) | 2024-05-08 | 2025-11-13 | F. Hoffmann-La Roche Ag | Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides |
| WO2026046995A1 (en) | 2024-08-28 | 2026-03-05 | Pairx Bio Pte. Ltd | T cell receptors and uses thereof |
| CN119074926B (zh) * | 2024-08-29 | 2025-11-25 | 中国医学科学院阜外医院深圳医院(深圳市孙逸仙心血管医院) | 一种靶向fap的car-t细胞在制备治疗心肌炎慢性期心脏纤维化的药物中的应用 |
| WO2026082710A1 (en) | 2024-10-16 | 2026-04-23 | F. Hoffmann-La Roche Ag | Small molecule-inducible recombinant receptors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| ATE417065T1 (de) | 2004-05-19 | 2008-12-15 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PL1871805T3 (pl) | 2005-02-07 | 2020-03-31 | Roche Glycart Ag | Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| UA118029C2 (uk) | 2013-04-29 | 2018-11-12 | Ф. Хоффманн-Ля Рош Аг | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US20170335281A1 (en) * | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| US20170151283A1 (en) * | 2014-05-23 | 2017-06-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating antibody resistance |
| CA2972714A1 (en) * | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
| KR102558502B1 (ko) | 2014-12-05 | 2023-07-20 | 시티 오브 호프 | Ｃｓ1 표적화된 키메라 항원 수용체-변형된 ｔ 세포 |
| WO2017072210A1 (en) | 2015-10-29 | 2017-05-04 | F. Hoffmann-La Roche Ag | Anti-variant fc-region antibodies and methods of use |
| KR20190133017A (ko) | 2017-03-27 | 2019-11-29 | 에프. 호프만-라 로슈 아게 | 개선된 항원 결합 수용체 구성 |
-
2018
- 2018-03-26 ES ES18712231T patent/ES3010117T3/es active Active
- 2018-03-26 CR CR20190440A patent/CR20190440A/es unknown
- 2018-03-26 MA MA049990A patent/MA49990A/fr unknown
- 2018-03-26 TW TW107110249A patent/TWI890655B/zh active
- 2018-03-26 UA UAA201910455A patent/UA128717C2/uk unknown
- 2018-03-26 PE PE2019001946A patent/PE20200152A1/es unknown
- 2018-03-26 IL IL269531A patent/IL269531B2/en unknown
- 2018-03-26 EP EP18712231.2A patent/EP3600407B1/en active Active
- 2018-03-26 MA MA049270A patent/MA49270A/fr unknown
- 2018-03-26 CA CA3056837A patent/CA3056837A1/en active Pending
- 2018-03-26 JP JP2019553013A patent/JP2020515256A/ja active Pending
- 2018-03-26 SG SG11201908796X patent/SG11201908796XA/en unknown
- 2018-03-26 MY MYPI2019005602A patent/MY205503A/en unknown
- 2018-03-26 CN CN201880034376.0A patent/CN110662560B/zh active Active
- 2018-03-26 MX MX2019011526A patent/MX2019011526A/es unknown
- 2018-03-26 KR KR1020197031539A patent/KR102712254B1/ko active Active
- 2018-03-26 AU AU2018241624A patent/AU2018241624B2/en active Active
- 2018-03-26 WO PCT/EP2018/057566 patent/WO2018177966A1/en not_active Ceased
- 2018-03-26 BR BR112019020168-8A patent/BR112019020168A2/pt unknown
-
2019
- 2019-09-19 US US16/576,546 patent/US11679127B2/en active Active
- 2019-09-24 CL CL2019002717A patent/CL2019002717A1/es unknown
- 2019-09-26 ZA ZA2019/06358A patent/ZA201906358B/en unknown
-
2023
- 2023-03-28 JP JP2023050868A patent/JP7642010B2/ja active Active
- 2023-05-04 US US18/312,339 patent/US12291561B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515256A5 (https=) | ||
| US11208459B2 (en) | Constructs having a SIRP-alpha domain or variant thereof | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| CN114341186B (zh) | 双特异性抗LRRC15和CD3ε抗体 | |
| CN108699157B (zh) | Psma结合抗体及其用途 | |
| AU2020213579B2 (en) | Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
| CN109715663A (zh) | 结合生长抑素受体2的异源二聚抗体 | |
| US20230355795A1 (en) | Immune antigen specific il-18 immunocytokines and uses thereof | |
| JP2020514375A5 (https=) | ||
| CN118496374A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| JP2018504092A5 (https=) | ||
| CN111712518A (zh) | 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途 | |
| CA3224147A1 (en) | Antibody conjugates and manufacture thereof | |
| WO2021207242A2 (en) | Anti-mesothelin antigen-binding molecules and uses thereof | |
| US20250163157A1 (en) | Bispecific antibodies against cd277 and a tumor-antigen | |
| US20250188166A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| WO2022057875A1 (zh) | 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途 | |
| CN117425484A (zh) | 多功能免疫细胞疗法 | |
| WO2023143535A1 (zh) | 一种靶向il-18bp的抗体及其应用 | |
| TW202241967A (zh) | 基於茚地那韋的化學二聚化ｔ細胞銜接器組成物 | |
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| CN121319180A (zh) | 靶向PD-L1和TGF-β的双功能分子 | |
| RU2019133202A (ru) | Улучшенные антигенсвязывающие рецепторы |